Skip to main content
. Author manuscript; available in PMC: 2014 Aug 11.
Published in final edited form as: Gynecol Oncol. 2012 Jun 1;127(1):55–62. doi: 10.1016/j.ygyno.2012.05.030

Figure 1.

Figure 1

In vitro effects of flavopiridol and cisplatin alone or in combination on viability and proliferation of OV202 (A) or CaOV3 (B) human ovarian cancer cells. Exposures of cells to all agents/combinations were of 26 hour duration (cisplatin applied 2 hours prior to combined flavopiridol/cisplatin exposure for 24 hours); cell growth assessed by observing confluence. (C) Predicted response surface for flavopiridol/cisplatin synergy model from SKOV3 human ovarian cancer cells, with Greco model parameters indicated in the adjacent table.